Dry AMD, geographic atrophy, and limits of drugs vs. restoration

45:00>> and that's the whole point. Yeah. Right. Right. >> Like that's that's where most of my information >> is coming from. >> Right. >> And that's the one that's more more common. Right. And then there's geographic atrophy. >> Um which it's it's at the end stage of AMD. you get these well demarcated patches of your retinal tissue where they die off. You get the photo receptors that are dying off. Um, and it results in like absolute scotoma. So, you get a blind spot right in the middle. >> And when you get the blind spot, you literally can't see in the middle of your visual field, >> which is so crazy, >> right? It's a complete loss of phototransuction. Mhm.

45:40>> Okay. That is what this particular study is trying to handle. Okay. >> And I it's it's pretty common actually. Irreversible blindness among older place older patients globally. You've got something like 200 million people that that have that have this. In the US itself, it's a million people. It's it's it's an incredibly like big problem that we need to solve, right? Obviously quality of life goes away. There's a loss of independence. It's got a devastating impact on >> I mean >> all aspects of your life >> especially like when you know not that this is it's true it's been true forever

46:23but particularly when everything's so device driven and and you know >> Oh yeah I didn't even think of that. >> You know what I mean? So it's like you have to be able to like you know read and interact with screens and so it's impossible to do so. >> Exactly. Um especially in a device- driven kind of era. >> Yeah. Yeah. And you know, previously it was just like, oh, you're just you're you're totally not having a good time. Okay. There are a few drugs like there's a there's the first drug was approved in 2023, is um there's another drug called uh cyov. I guess the mechanism is you basically

47:03inhibit this cascade of stuff that's going wrong in the back back of your retina. It slows the lesion growth by 20%. But at the end of the day, it's not restorative. >> It's just stopping. >> It's just slowing it down. >> The degeneration, >> right? And that's that's great. >> Yes. >> But >> yes, >> for someone who's already had it, >> it's not really doing much. >> It's not Yeah. And so now we've got this